^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Junshida (ongericimab)

    i
    Other names: JS002
    Associations

    News

    Trials
    Company:
    Chongqing Bochuang Pharmaceuticals, Shanghai Junshi Biosci
    Drug class:
    PCSK9 inhibitor
    Related drugs:
    Associations

    News

    Trials
    21d
    ORIS: Ongericimab Injection Reducing Recurrence of Ischemic Stroke (clinicaltrials.gov)
    P3, N=4398, Not yet recruiting, Beijing Tiantan Hospital
    New P3 trial
    |
    Junshida (ongericimab)
    4ms
    ONTOP: Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial (clinicaltrials.gov)
    P2, N=32, Not yet recruiting, Shanghai Pudong Hospital
    New P2 trial • pMMR
    |
    Avastin (bevacizumab) • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • oxaliplatin • irinotecan • leucovorin calcium • Junshida (ongericimab)
    almost4years
    A Study Explore JS001+JS002 in Patients With Advanced Cancer (clinicaltrials.gov)
    P1, N=114, Recruiting, Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    Loqtorzi (toripalimab-tpzi) • Junshida (ongericimab)
    4years
    A Study Explore JS001+JS002 in Patients With Advanced Cancer (clinicaltrials.gov)
    P1, N=114, Not yet recruiting, Shanghai Junshi Bioscience Co., Ltd.
    New P1 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Loqtorzi (toripalimab-tpzi) • Junshida (ongericimab)